Raia Drogasil (OTCMKTS:RADLY) Shares Gap Down - What's Next?

Key Points

• Shares gapped down: Raia Drogasil opened at $4.46 after a prior close of $4.70 and last traded at $4.46 on light volume (888 shares).
• Analyst view: Zacks Research recently raised the stock to a "Hold" and the consensus rating per MarketBeat is currently Hold.
• Technicals: The 50‑day moving average is $4.65 and the 200‑day moving average is $4.49, leaving the stock below its 50‑day but roughly in line with the 200‑day level.

Raia Drogasil S.A. (OTCMKTS:RADLY - Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $4.70, but opened at $4.46. Raia Drogasil shares last traded at $4.46, with a volume of 888 shares traded.

Analysts Set New Price Targets

Separately, Zacks Research raised Raia Drogasil to a "hold" rating in a research note on Thursday, April 9th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of "Hold".

Raia Drogasil Stock Performance

The company's 50 day moving average price is $4.65 and its 200-day moving average price is $4.49.

About Raia Drogasil

Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.

The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.